Article ; Online: Central Nervous System Lymphoma: Novel Therapies.
Current treatment options in oncology
2022 Volume 23, Issue 1, Page(s) 117–136
Abstract: Opinion statement: Primary central nervous system lymphomas (PCNSLs) are very rare neoplasms and continue to be challenging to treat. While high-dose methotrexate (HD-MTX)-based regimens are the currently accepted standard first-line therapy for newly ... ...
Abstract | Opinion statement: Primary central nervous system lymphomas (PCNSLs) are very rare neoplasms and continue to be challenging to treat. While high-dose methotrexate (HD-MTX)-based regimens are the currently accepted standard first-line therapy for newly diagnosed patients, the optimal induction therapies are still unknown. The role of consolidation therapies continues to evolve with a variety of chemotherapy regimens, including high-dose chemotherapy with stem cell rescue and reduced or deferred whole brain radiotherapy being used. Importantly, several recent advances have been made in the treatment of PCNSL. The incorporation of targeted therapy and immune therapy remain promising strategies. Several agents, successfully used in treatment of systemic lymphomas, have shown activity in PCNSL, frequently leading to durable responses in the relapsed/refractory patients. Many ongoing studies will likely lead to a better understanding of the roles of these treatments, especially as the first line and potentially also as maintenance. In addition, the use of molecular profiling to predict disease response to targeted agents and understand relapse patterns will become increasingly important. Clinical trials in PCNSL are critical yet frequently challenging to conduct given the rarity of the condition and lack of suitable subjects. Therefore, multi-institutional and international collaboration is of utmost importance to accelerate progress in understanding the biology and design better treatments for this disease. It is critical to consider patients of all demographics in the design and study of future treatment algorithms to have the largest impact on patient care and outcomes. |
---|---|
MeSH term(s) | Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Central Nervous System/pathology ; Central Nervous System Neoplasms/diagnosis ; Central Nervous System Neoplasms/etiology ; Central Nervous System Neoplasms/therapy ; Humans ; Lymphoma/diagnosis ; Lymphoma/etiology ; Lymphoma/therapy ; Lymphoma, Non-Hodgkin/drug therapy ; Methotrexate/therapeutic use ; Neoplasm Recurrence, Local/drug therapy |
Chemical Substances | Methotrexate (YL5FZ2Y5U1) |
Language | English |
Publishing date | 2022-02-19 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 2057351-0 |
ISSN | 1534-6277 ; 1527-2729 |
ISSN (online) | 1534-6277 |
ISSN | 1527-2729 |
DOI | 10.1007/s11864-021-00921-5 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5523: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.